Aerie Pharmaceuticals’ (AERI) “Positive” Rating Reiterated at Canaccord Genuity
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)‘s stock had its “positive” rating reiterated by analysts at Canaccord Genuity in a research report issued to clients and investors on Monday, The Fly reports. They currently have a $73.00 price objective on the stock, up from their prior price objective of $65.00. Canaccord Genuity’s price target points to a potential upside of 18.80% from the company’s previous close.
Several other analysts have also recently commented on AERI. Stifel Nicolaus increased their target price on Aerie Pharmaceuticals from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Tuesday, July 4th. Zacks Investment Research cut Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Cantor Fitzgerald restated an “overweight” rating and set a $62.00 target price (up previously from $56.00) on shares of Aerie Pharmaceuticals in a report on Thursday, July 20th. BidaskClub upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, July 24th. Finally, HC Wainwright set a $69.00 target price on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $68.92.
Shares of Aerie Pharmaceuticals (NASDAQ AERI) opened at 61.45 on Monday. The firm’s market cap is $2.23 billion. Aerie Pharmaceuticals has a 12-month low of $32.05 and a 12-month high of $66.10. The company has a 50-day moving average of $55.46 and a 200 day moving average of $50.89.
Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.02. Equities analysts predict that Aerie Pharmaceuticals will post ($2.59) EPS for the current year.
TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/16/aerie-pharmaceuticals-aeri-positive-rating-reiterated-at-canaccord-genuity.html.
A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in Aerie Pharmaceuticals by 113,376.8% in the first quarter. BlackRock Inc. now owns 2,600,888 shares of the company’s stock valued at $117,951,000 after buying an additional 2,598,596 shares during the period. Vanguard Group Inc. lifted its stake in Aerie Pharmaceuticals by 55.0% in the second quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock valued at $113,446,000 after buying an additional 766,300 shares during the period. Senzar Asset Management LLC acquired a new position in Aerie Pharmaceuticals in the second quarter valued at about $20,568,000. Broadfin Capital LLC acquired a new position in Aerie Pharmaceuticals in the second quarter valued at about $16,291,000. Finally, AXA acquired a new position in Aerie Pharmaceuticals in the second quarter valued at about $10,961,000. Institutional investors and hedge funds own 94.64% of the company’s stock.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.